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Abstract
We investigated the immunohistochemical distribution
of 3 components of the renin-angiotensin system (RAS),
angiotensin-converting enzyme (ACE), angiotensin II
(AngII) and AT1 receptor (AT1), in the human eye. ACE
and AngII were localized to nonpigmented epithelial cells
of the ciliary body, to endothelial and epithelial cells of
the cornea, to epithelial cells of the conjunctiva and to
trabecular meshwork cells in the anterior part of the eye.
In the posterior part of the eye, ACE and AngII were local-
ized to ganglion cells, some cells in the inner nuclear
layer, photoreceptor cells and to endothelial cells of the
retinal and choroidal vessels. The overall intensity of AT1
immunoreactivity was weak in all ocular tissues, but the
main localization was in ganglion cells. As a preliminary
investigation, we were able to include 2 Alzheimer’s dis-
ease (AD) cases. In AD, no differences from controls
were found in the cellular distribution and staining inten-
sity of all 3 antigens. The manifold localization sites of
the observed antigens point to rather generalized func-
tions of the RAS in human ocular tissues, such as regula-
tory effects on neuronal cells, vessels and vitreous hu-
mor homeostasis.
Copyright © 2004 S. Karger AG, Basel
Introduction
The renin-angiotensin system (RAS) is mainly impli-
cated in the regulation of fluid homeostasis and blood
pressure. Angiotensin II (AngII) is the vasoactive peptide
generated from the inactive peptide angiotensin I by the
enzymatic action of angiotensin-converting enzyme (ACE)
[1–3]. Angiotensin I, on the other hand, is generated by the
enzyme renin acting on the substrate angiotensinogen. The
first evidence that the CNS may have its own endogenous
RAS demonstrated the presence of precursor peptides and
synthesizing enzyme ACE in the canine brain [4–6]. It is
now well known that all components of the RAS exist in
the brain [7]. Besides its action as a vasoactive peptide,
AngII, as the active component of the RAS, exerts modula-
tory actions on neurons in the CNS [8, 9].
The immunohistochemical localizations of AngII and
ACE in different brain regions has been well studied in
rats [10–12] and humans [8, 9, 13], in particular the corti-
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cal distribution of the AT1 receptor (AT1), a 7-transmem-
brane receptor coupled to phospholipase C, calcium and
cAMP second-messenger systems, which mediates most
of the actions of AngII including blood pressure regula-
tion and growth-promoting effects [2, 8, 14, 15].
Ocular structures which belong to the CNS have their
own intraocular RAS independent of circulating RAS
peptides [16, 17]. There is biochemical and immunohisto-
chemical evidence for the localization of angiontensino-
gen, the precursor protein of angiotensins [18], AngII [19],
ACE [17, 20] and AT1 [21, 22] in ocular neurons and ves-
sels of rodents. In the human eye, angiotensin and ACE
gene expressions have been identified, supporting the
concept of intraocular synthesis of AngII, independent of
precursor substances in the circulation [17]. Besides its
vascular effects [23], the intraocular RAS has been postu-
lated to have neuromodulatory functions, and, here, it
may contribute to local pathologies such as proliferative
retinopathy [16, 17].
The role of ocular RAS during the course of neurode-
generation has not been studied yet. Studies in Alzheim-
er’s disease (AD) patients indicate a possible link between
RAS activity and cognitive decline [3, 24]. Vascular fac-
tors resulting from RAS disturbances may precede AD
[25]. Indeed, ACE activity has been found to be increased
in the cortex of AD patients [1, 8, 26] parallel to a decrease
in the cerebrospinal fluid levels [27]. Although contrary
results exist, most of the case-control studies indicate that
ACE gene polymorphism may provide a genetic suscepti-
bility factor for AD [24, 28, 29]. The aim of the present
study was to explore the morphological localizations of
ACE, AngII and AT1 in human ocular tissues and to
reveal possible alterations of the RAS in AD with immu-
nohistochemistry.
Materials and Methods
Paraffin-embedded human ocular samples were used. The non-
opened eye globes were fixed in 4% paraformaldehyde for 2 days and
cut in the sagittal plane into 4-Ìm-thick consecutive sections includ-
ing peripheral, central and macular regions. The study consisted of 9
controls and 2 AD cases (table 1). The mean postmortem delay was
23 h 57 min for controls and 16 h 15 min for AD cases (table 1). The
diagnosis of AD was made with clinical evaluation and confirmed by
postmortem neuropathological examination. In most cases, the cause
of death was heart failure or pneumonia. The sample collection was
approved by the Ethics Committee criteria and according to the Hel-
sinki Declaration of 1975.
The antigens were visualized by peroxidase staining using the
substrate 3-amino-9-ethylcarbazole according to the manufacturer’s
instructions (Vector Laboratories). The method for immunohisto-
chemistry has been described in detail elsewhere [30]. The primary
Table 1. Data of control (C) and AD cases
Case Clinical
diagnosis
Age
years
Gender PMD CD
1 C 85 M 31 h heart failure
2 C 97 F 26 h heart failure
3 C 91 F 24 h heart failure
4 C 69 F 20 h pancreatitis
5 C 76 F 9 h 40 min heart failure
6 C 88 F 31 h heart failure
7 C 76 F 9 h pneumonia
8 C 92 M 24 h 32 min heart failure
9 C 85 F 6 h 33 min heart failure
1 AD 83 M 15 h heart failure
2 AD 84 M 17 h 30 min pneumonia
PMD = Postmortem delay; CD = cause of death.
antibodies used were a mouse monoclonal antibody against the N-
terminal end of human ACE (Chemicon International, Temecula,
Calif., USA), an affinity-purified rabbit polyclonal antibody raised
against a peptide corresponding to the amino acids 306–359 of the
AT1 of human origin (Santa Cruz Biotechnology, Santa Cruz, Calif.,
USA) and a rabbit anti-AngII (human) serum (Phoenix Pharmaceuti-
cals, Belmont, Calif., USA). The specificity of the antibodies has
been ascertained by previous experiments [31, 32]. The optimal con-
centration of the primary antibody was experimentally determined
to be 1:100 for all antibodies. The samples were counterstained with
Mayer’s hemalum. The experiments were performed in duplicate.
Control samples were stained simultaneously following the same pro-
cedure as the test samples with the exception that the primary anti-
bodies were omitted. All sections were assessed for localization and
intensity of specific immunoreactivity on a semiquantitative scale of
+/+++ by two blind observers (table 2).
Results
The results presented here localize ACE, AngII and
AT1 immunoreactivities to different cellular and vascular
structures within the human eye. For cytoarchitectural
organization of ocular cells, we follow the detailed de-
scriptions by Spencer [33]. For the clarity of the overview
the anterior and posterior compartments will be discussed
separately, and the results are summarized in table 2
according to regional distribution and staining intensity.
Anterior Part of the Eye
In the anterior part of the human eye, the cornea and
ciliary body belong to the regions where notable amounts
of immunoreactive structures were present (table 2). In
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Table 2. Semiquantitative assessment of the intensity of AngII-, ACE- and AT1-immunoreactive structures in the
human eye
Anterior eye
cornea
ACE AT1 AngII
ciliary body
ACE AT1 AngII
Posterior eye
retina
ACE AT1 AngII
choroidea
ACE AT1 AngII
Controls 1 + – + – – + ++ – ++ + – –
2 + + ++ ++ – + ++ + ++ + – –
3 + – + + – + ++ – ++ + – +
4 ++ + +++ + – + ++ – ++ + – –
5 + + ++ + – + + – + + – –
6 + – + + – + + + ++ + – –
7 + – + – – + + – + – – –
8 + + + + – + ++ – ++ + – –
9 ++ + ++ + – + ++ – ++ – – +
AD 1 ++ – ++ + – + ++ – ++ + – +
2 ++ – ++ – – + + – + + – –
– = No immunoreactivity; + = slight; ++ = moderate; +++ = high.
the ciliary body, nonpigmented epithelial cells presented
intracellular staining for ACE and AngII (fig. 1A, B),
whereas we could not observe any AT1 immunoreactivity
in this cellular localization. Endothelial and epithelial
cells of the cornea were distinctly immunoreactive for
both ACE and AngII in some cases (fig. 1E, F). AT1
immunoreactivity was also present on the surface of these
cells, but the overall intensity of the immunoreaction was
weak, even missing in about half of the cases. In addition,
single cells in the cornea, distinctly recognized as keroto-
cytes, were immunolabeled for AngII. Both ACE and
AngII immunoreactivities were also present in the epithe-
lial cells of the conjunctiva where we were not able to
detect AT1 labeling. Within the stroma of the iris single
blood vessels were immunoreactive for ACE and AngII in
their endothelial cells. Finally, trabecular meshwork cells
were mostly labeled for both ACE and AngII (fig. 1D).
The lens belonged to the regions displaying no staining for
the RAS components. In AD cases, the cellular localiza-
tions and staining intensity for ACE, AngII and AT1 were
comparable with the findings in controls (table 2).
Posterior Part of the Eye
The retina revealed the most intense labeling for the
RAS components ACE and AngII within the whole eye.
The inner region of the limiting membrane was distinctly
positive for ACE and AngII in its entire length (fig. 2A–
C). In the ganglion cell layer (GCL), some of the ganglion
cells with round somata, 10–14 Ìm in diameter and with a
vesicular nucleus, were stained for both ACE and AngII
(fig. 2A–C), whereas the AT1 immunoreactivity was very
weak and was found only in 2 controls on the cellular sur-
face of the ganglion cells (table 2). The GCL contained
also some ACE- and AngII-positive cellular processes.
The endothelia of small vessels within the GCL were posi-
tive for ACE and AngII. Some immunoreactive cells (ac-
cording to their shape probably bipolar cells) were scat-
tered in the inner nucleiform layer (fig. 2B). In addition to
the GCL and the inner plexiform layer, the outer plexi-
form layer contained cellular processes entirely stained
for ACE and AngII. Both the outer nucleiform layer, con-
taining the cell somata of the photoreceptor cells, and the
inner segments of these cells were stained for ACE and
AngII (fig. 2A–C).
Fig. 1. Sagittal sections through the anterior part of the human eye.
ACE- (A) and AngII-immunoreactive (B) cells in the nonpigmented
epithelium of the ciliary body as indicated by arrows. Low magnifica-
tion (LM), scale bar = 50 Ìm. C Control section through the ciliary
body stained simultaneously following the same procedure, with the
exception that the primary antibody was omitted. LM. D AngII
immunoreactivity in the trabecular meshwork (arrows). High magni-
fication (HM), scale bar = 120 Ìm. ACE- (E) and AngII-immunoreac-
tive (F) endothelial cells of the cornea as indicated by arrows. HM. 
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In the choroidea, endothelial cells of the large vessels
displayed ACE and AngII immunoreactivity (fig. 2F), but
no staining for AT1. The same was true for the central
vessels within the optic nerve. Sclera contained no immu-
noreactive structures. As in the anterior part of the eye,
there were no differences in cellular distribution and
staining intensity of the observed immunoreactivities be-
tween controls and AD cases.
Discussion
The data presented here reveal the differentiated local-
ization of the main RAS components in the human eye.
The results support previous findings that ACE is present
in ocular cells suggesting the local synthesis of AngII [17]
and provide additional information on the cellular local-
ization of AngII and its specific receptor AT1. In the
aforementioned study, pooled tissue samples were used,
and, using reverse-transcription polymerase chain reac-
tion, gene expressions of renin, angiotensinogen and ACE
were localized to the human retinal pigment epithelium,
choroid and neural retina [17]. Angiotensinogen and ACE
mRNAs were also found marginally in sclera samples.
Our data complete these findings with the additional
description of the RAS components in the anterior part of
the eye and their immunohistochemical localization to
distinct cells. Since 18 subjects with a mean age of 54
years and a range up to 78 years were included in the pre-
vious study in the human eye [17], the study samples are
comparable with the elderly subjects in our study.
Fig. 2. Sagittal sections through the posterior part of the human eye.
ILM = Inner limiting membrane; GCL = ganglion cell layer; GC =
ganglion cells; IPL = inner plexiform layer; INL = inner nucleiform
layer; OPL = outer plexiform layer; ONL = outer nucleiform layer
consisting of cell somata of photoreceptor cells; IS = inner segments
of photoreceptor cells; CV = choroidal vessels. LM = Low magnifica-
tion (scale bar = 50 Ìm); HM = high magnification (scale bar =
120 Ìm). Low (A) and high (B) magnifications of ACE-immunoreac-
tive structures in the retina. In B, ACE-immunoreactive ganglion
cells are indicated by an arrow. C AngII-immunoreactive structures
in the retina. LM. D AT1 immunoreactivity is very weak or even
missing in the retina. LM. E Control section stained simultaneously
following the same procedure, with the exception that the primary
antibody was omitted. LM. F Choroidal vessels revealing ACE
immunoreactivity in their endothelial cells. HM. 
AngII acting within the ocular tissues has been suggest-
ed to be local in origin since its leakage from the circula-
tion is minimal or even nonexistent, and both precursor
and synthesizing enzymes are present within the eye [19].
The retinal pigment epithelium separates the retina from
the choroid and forms, together with the pigment epithe-
lium of the ciliary body and the endothelium of the retina
vessels, the blood-retina barrier preventing the diffusion
of circulatory RAS components [19, 34, 35]. AngII con-
centration in the vitreous humor has been found to be
only about 10% of the plasma concentration, and in the
retina and choroid it was 10 and 86 times higher, respec-
tively, than in plasma [19] indicating a concentration of
AngII synthesis in the outer part of the eye [17]. This
interpretation is supported by the finding that a renin/
prorenin gradient exists in vitreous humor, with the low-
est levels present in the most anterior parts of the vitreous
[36]. The previous study failed to show renin mRNA
expression in the anterior part of the human eye [17].
However, in the bovine eye, renin has also been found in
the anterior part [36]. Our data clearly show that ACE and
AngII are present both in anterior and posterior parts of
the eye supporting the hypothesis of local synthesis of
AngII in the whole structure.
In the anterior part of the eye, ACE and AngII were
mainly localized to endothelial and epithelial cells of the
cornea and to nonpigmented cells of the ciliary body. The
ciliary body is also the main localization for renin in the
anterior part of the eye in a previous study in bovine ocu-
lar tissues [36]. Besides its expression in the posterior part
of the eye, ACE mRNA has also been detected in the iris/
ciliary body of the chicken eye [20]. It has been suggested
that vasoconstriction in this well-vascularized area can be
modulated by the local RAS, independently of the circula-
tion-derived AngII and also independently of ACE syn-
thesis by the other tissues [20], which is supported by our
findings that both ACE and AngII are present in cellular
localizations here. In addition to cellular structures, small
vessels in the anterior area were positive for ACE. The
effects of ACE inhibitors as highly effective antiglaucoma-
tous substances lowering intraocular pressure [37] and
preventing angiogenesis reducing the risk of diabetic pro-
liferative retinopathy [38] may be explained by their
actions on ocular vessels [20]. Since the epithelium of the
ciliary body is the site of aqueous humor secretion [39],
and the trabecular meshwork cells, which were immuno-
positive for both ACE and AngII in our series, are the
main site of outflow facility [33], the ocular RAS in this
region may be importantly involved in the regulation of
aqueous humor outflow regulation.
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The cellular localizations of ACE and AngII in the pos-
terior part of the eye confirm previous findings in chicken
[20, 40], rat [22], rabbit [19] and human [17] retina. In our
series, the ACE- and AngII-immunoreactive cells in the
GCL were clearly ganglion cells and the positive cells in
the inner nucleiform layer may correspond to bipolar
cells, probably amacrine or Müller cells. Similar to our
results, ACE and AngII have been found localized to gan-
glion, amacrine, bipolar and photoreceptor cells in the
retina [19, 20]. It has been suggested that amacrine cells
account mainly for AngII synthesis in the retina [19]
whereas ACE may be not an intrinsic enzyme of the
AngII-positive amacrine cells but rather taken up from
the intracellular space [20]. AngII in the retina may pri-
marily act as a neurotransmitter or neuromodulator [16,
19]. Besides AngII, substance P has been identified as a
target neuropeptide for the catabolic activities of ACE in
the retina [41] emphasizing the neuromodulatory role of
the RAS in this area. In particular, the ganglion cells were
strongly immunoreactive for ACE and AngII in our study.
The suprachiasmatic nucleus, the principal circadian pa-
cemaker in mammals, receives efferent projections from
the ganglion cells providing light information to entrain
circadian rhythms [30, 42] and contains AngII-positive
neurons [43] suggesting a possible neuromodulatory role
for the RAS in this pathway.
In the present study, both ACE and AngII were local-
ized to the inner segments of photoreceptor cells. ACE
immunoreactivity in photoreceptor cells has also been
previously described [19, 40], but, in contrast to the
present study, these reports have failed to localize AngII
in photoreceptor cells. It has been suggested that ACE
may act predominantly as a general peptidase here. Our
findings provide evidence for the presence of AngII in
photoreceptor cells, but, since the mentioned previous
studies were not performed in humans, we cannot exclude
interspecies differences.
AT1 immunoreactivity was slight in ocular tissues.
The detected immunoreaction was restricted to corneal
cells in the anterior part of the eye and to ganglion cells in
the retina. The overall intensity of the AT1 immunoreac-
tivity was very weak, and, in the retina, it could be
detected only in 2 controls. AT1 mRNA has been found in
the rat retina, iris/ciliary body and choroid by reverse-
transcription polymerase chain reaction [21, 22]. In only
one study using immunohistochemistry AT1 has been
localized to ganglion cells in the rat retina [22]. Since the
same AT1 antibody was used in our and the latter study
[22], species-specific differences may account for the dis-
crepancy. However, taken together, the results identify
ganglion cells as a favored action site of AngII. This
hypothesis is supported by the observation that AngII
modulates the calcium concentration of retinal ganglion
cells [44] emphasizing the role of AngII as a neuromodula-
tory substance.
ACE- and AngII-immunoreactive vessels were found
both in the GCL and choroidea, but no AT1 immunoreac-
tivity. This is in contrast with findings in the rat eye where
AT1 has been found to be expressed in the uveal and epi-
retinal arteries, but not in the vessels of the inner retina
leading to the suggestion that the neuronal retina may be
not involved in vasoconstrictive functions [22]. Our data
show that the RAS may be vasoactive both in the retina
and choroidea. The blood supply of the human eye origi-
nates from the arteria ophthalmica but separates to two
different sources, the arteria centralis retinae and choroi-
dal vessels, supplying the retina and the choroidea sepa-
rately [33]. The RAS may be effective in both vessel sys-
tems, but the vasoactive RAS components in the choroi-
dea may be, in contrast to retinal ACE and AngII, of circu-
latory origin, since both parts are separated by a blood-
retina barrier [19, 34, 35]. Besides its neuromodulatory
actions, AngII in the retina has vascular growth-promot-
ing effects, inducing neovascularization via angiopoietin
2, and, therefore, plays a role in the progression of prolif-
erative retinopathies in diabetes [45] extending the spec-
trum of RAS actions in the retina.
Neither the intensity nor the distribution of the ob-
served immunoreactivities was altered in the 2 AD cases.
In the CNS, findings are different: ACE density was
increased in the cortex [1, 8, 26] and in the striatum [1] of
AD patients parallel to an increased AngII immunoreac-
tivity in the AD hippocampus and striatum [8]. Physiopa-
thological hypotheses suggest a possible involvement of
the RAS components in the course of AD [24]. Most of the
performed case-control studies tend to suggest that the
ACE genetic polymorphism may constitute a genetic sus-
ceptibility factor for AD [24] and RAS disturbances may
contribute to the vascular pathology observed in AD [25].
Indeed, AngII immunoreactivity has been found to be
increased around small vessels in AD striatum supporting
the hypothesis of an underlying vascular pathology in AD
[8]. Several reasons may account for the finding that the
RAS components were not altered in the AD cases. First,
only 2 AD cases could be included in the study, which
precludes any generalization. Second, the diagnosis of the
2 AD cases confirmed with postmortem pathological
examination excluded the possibility that these had a dis-
tinct vascular pathology. It may be that those dementia
cases with more prominent vascular involvement are the
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ones showing RAS alterations. Third, RAS alterations
previously observed in AD were particularly localized in
brain regions such as the hippocampus or cortex, which
are highly and early implicated in AD pathology. RAS in
ocular tissues may not have the same impact on AD
pathology as brain regions involved in higher cognitive
functions. Nevertheless, the present data confirm that
ocular RAS alterations may contribute to pathological
changes of ocular fluid homeostasis, angiogenesis and
local neuromodulatory actions.
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